WolverHeme Happy Hour

著者: Bernard Marini Anthony Perissinotti et al.
  • サマリー

  • Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
    Bernard Marini, Anthony Perissinotti, et al.
    続きを読む 一部表示

あらすじ・解説

Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
Bernard Marini, Anthony Perissinotti, et al.
エピソード
  • Dex and the Cytokine City: Managing CRS with Bispecifics
    2025/04/07

    In this episode, Bernie and Anthony are joined by 3 hematology pharmacists - James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; and Justine Preedit, PharmD, BCOP - to discuss the optimal management of CRS in patients receiving bispecific antibodies!


    Inspired by this recent paper:

    https://www.nature.com/articles/s41408-025-01222-y

    続きを読む 一部表示
    1 時間
  • LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML
    2025/03/11

    In this episode, Bernie and Anthony are joined by Dr. Charlie Foucar and Dr. Anand Patel to review the interesting and controversy-filled saga of gemtuzumab in AML? Should we be using this agent in AML? Tune in to find out!

    続きを読む 一部表示
    1 時間 5 分
  • Episode 32: Navigating a BlinatumoMAD World
    2025/01/21

    In this episode, Anthony and Bernie are joined by two special guests to discuss recent updates to the use of blinatumomab in both adult and pediatric acute lymphoblastic leukemia (ALL), including the results of the AALL1731 trial and the full publication of ECOG1910.

    Julia Brown, PharmD, a Pediatric Hematology/Oncology Clinical Pharmacist and Lydia Benitez, an Adult Outpatient Leukemia Clinical Pharmacist bring their unique perspectives and expertise on the proper incorporation of blinatumomab into ALL care, as well as some of the major practical nuances that will be helpful to providers across the globe!

    Finally, for all of the Oncology Pharmacists in the audience, don't forget to fill out the HOPA Practice Outcomes and Professional Benchmarking Committee Survey!

    続きを読む 一部表示
    1 時間 6 分

WolverHeme Happy Hourに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。